Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is characterized by a high rate of metastasis ...

The FDA approved Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma, according to a press ...

Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its ...

The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive ...

The anti-GPC3 targeted therapies market is expected to witness growth in the coming years, driven by the increasing incidence of cancer cases, clinical pipeline activity, and anticipated regulatory ...

Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food ...

Approval was based on results from the DOORwaY90 trial, which demonstrated a 98.5% overall response rate and 100% local tumor control in patients treated with the SIR-Spheres Y-90 resin microspheres ...

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in ...

Sirtex Medical’s SIR-Spheres Y-90 resin microspheres receive US FDA nod to treat unresectable hepatocellular carcinoma: Woburn, Massachusetts Tuesday, July 8, 2025, 17:00 Hrs [I ...

versus the standard of care alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC). "This regulatory clearance to proceed with a pivotal trial in ...

A hepatocellular carcinoma risk score using routine clinical data outdid the FIB-4 alone in identifying at-risk patients without viral hepatitis or cirrhosis.

Therapies targeting PD-1/PD-L1 have become first line therapies for patients with hepatocellular carcinoma (HCC) but response rates remain limited.